Med Ed Report briefs: September 2012

Med Ed Report briefs: September 2012
Med Ed Report briefs: September 2012

The Alliance for Continuing Education in the Health Professions (ACEHP) named Robin King (pictured) its new executive director. King will oversee operational and financial aspects of the group, replacing Paul Weber, who retired at the end of May.

ACCME-accredited provider Med-IQ hired Donna Harris as director of educational grant development. She has 10 years of experience in healthcare, including senior CME experience in grant and business development.

The AAFP issued a position paper on opioid abuse and pain management, opposing mandated CME as a prerequisite to DEA registration or licensure, and “any other barriers to family physicians' ability to prescribe these drugs.”
 
The AMA is revising its online pain management CME to provide state-of-the-art educational modules, including specific guidance on responsible opioid prescribing, the chair of the AMA board of trustees wrote in AMedNews.com.
 
EthosCE, a learning management system for continuing education, said Elsevier signed a contract for EthosCE PRO edition to support the publisher's office of CME ­operations.
You must be a registered member of MMM to post a comment.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.